Sign in Register

Braftovi (encorafenib)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

USES: Encorafenib is used to treat certain types of cancer (such as lung cancer, melanoma skin cancer, cancer in the colon or rectum). Encorafenib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Generic name: encorafenib
Pronunciation: (EN-koe-RAF-e-nib)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Braftovi

Intelligence content is not available yet.

Indications

The following indications are listed for Braftovi:

  • Malignant Melanoma With Braf V600e Mutation
  • Malignant Melanoma With Braf V600k Mutation
  • Metastatic Colorectal Cancer With Braf V600e Mutation
  • Non-Small Cell Lung Cancer With Braf V600e Mutation

Also known as: Melanoma With Braf V600e Genetic Mutation, Nsclc With Braf V600e Mutation.

Dosing

No dosing information is available for this tab.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data